Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy

被引:60
|
作者
Torres, A [1 ]
Domínguez-Gil, B [1 ]
Carreño, A [1 ]
Hernández, E [1 ]
Morales, E [1 ]
Segura, J [1 ]
González, E [1 ]
Praga, M [1 ]
机构
[1] Hosp Univ 12 Octubre, Serv Nefrol, Dept Nephrol, Madrid 28041, Spain
关键词
nephrotic syndrome; immunosuppression; progressive renal disease; kidney deterioration; proteinuria; renal failure;
D O I
10.1046/j.1523-1755.2002.00124.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Treatment of idiopathic membranous glomerulonephritis (MGN) is a controversial issue. Whereas some authors recommend early immunosuppressive treatment of all patients with nephrotic syndrome, others do not support aggressive therapies, based on the spontaneous long-term favorable outcome of most patients. However, 20 to 50% of untreated patients develop progressive renal insufficiency. Methods. All of the patients with biopsy-proven MGN who developed renal insufficiency at our Hospital during the period of 1975 to 2000 were studied. Selected patients (N = 39) were separated into two groups according to the two different therapeutic policies followed at our department: a conservative approach during the first period, 1975 to 1989 (group I, N = 20), and a course of immunosuppressive therapy (oral prednisone for six months and concurrent oral chlorambucil, 0.15 mg/kg/day, during the first 14 weeks) during the second period, 1990 to 2000 (group II, N = 19). Results. There were no significant differences between both groups at the time of renal biopsy, nor at the onset of renal function decline. All group I patients showed a progressive renal insufficiency; at the end of the follow-up 13 patients (65%) were on chronic dialysis, 2 (10%) showed advanced renal failure, and 5 (25%) had died. In contrast, most of group II patients showed an improvement or stabilization of serum creatinine (S-Cr; 2.3 +/- 0.9 mg/dL at onset of treatment, 2 +/- 1.5 mg/dL at the end of follow-up) together with decreased proteinuria (11.2 +/- 3.3 vs. 5.2 +/- 6.7 g/24 h). At the end of the follow-up 58% of group II patients had a S-Cr value less than or equal to1.5 mg/dL and 36% showed a complete or partial remission, whereas no patient in group I showed remission. After four years of follow-up the probability of renal survival without dialysis was 55% in group I and 90% in group II (P < 0.001), and after seven years the renal survival was 20% and 90%, respectively (P < 0.001). Side effects of immunosuppressive treatment were uncommon but severe, as two patients suffered Pneumocystis carinii pneumonia. Conclusion. A course of immunosuppressive treatment administered early at the onset of renal function decline induces a favorable effect in most of patients with MGN and deteriorating renal function. Untreated patients progressed without exception toward advanced renal failure.
引用
收藏
页码:219 / 227
页数:9
相关论文
共 50 条
  • [1] Immunosuppressive treatment of idiopathic membranous nephropathy: the dilemma continues
    Filippone, Edward J.
    [J]. CLINICAL NEPHROLOGY, 2013, 79 (02) : 143 - 153
  • [2] Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review
    Perna, A
    Schieppati, A
    Zamora, J
    Giuliano, GA
    Braun, N
    Remuzzi, G
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (03) : 385 - 401
  • [3] Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome
    Chen, Yizhi
    Schieppati, Arrigo
    Chen, Xiangmei
    Cai, Guangyan
    Zamora, Javier
    Giuliano, Giovanni A.
    Braun, Norbert
    Perna, Annalisa
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (10):
  • [4] IMMUNOSUPPRESSIVE TREATMENT IN MEMBRANOUS NEPHROPATHY
    LEDINGHAM, JGG
    [J]. QUARTERLY JOURNAL OF MEDICINE, 1990, 74 (274): : 117 - 119
  • [5] An overview of immunosuppressive therapy in idiopathic membranous nephropathy
    Maas, R. J.
    Hofstra, J. M.
    Wetzels, J. F.
    [J]. MINERVA MEDICA, 2012, 103 (04) : 253 - 266
  • [6] Leflunomide in idiopathic membranous nephropathy: A new immunosuppressive with promising treatment potential
    Chen, Chien-Liang
    Hsu, Chih-Yang
    Fang, Hua-Chang
    [J]. NEPHROLOGY, 2014, 19 (01) : 1 - 2
  • [7] Early initiation of immunosuppressive treatment in membranous nephropathy patients
    Chan, Chieh Kai
    Lai, Tai Shuan
    Chen, Ping Min
    Chou, Yu Hsiang
    Wu, Ching Fang
    Chiu, Yen Ling
    Chiang, Wen Chih
    Chen, Yung Ming
    Chu, Tzong-Shinn
    Wu, Kwan Dun
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (04) : 266 - 275
  • [8] Treatment of Idiopathic Membranous Nephropathy
    Waldman, Meryl
    Austin, Howard A., III
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (10): : 1617 - 1630
  • [9] TREATMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY
    WARDLE, EN
    [J]. LANCET, 1994, 343 (8892): : 291 - 291
  • [10] Treatment of idiopathic membranous nephropathy
    Hofstra, Julia M.
    Fervenza, Fernando C.
    Wetzels, Jack F. M.
    [J]. NATURE REVIEWS NEPHROLOGY, 2013, 9 (08) : 443 - 458